Amdocal Pro 2.5 mg+5 mg

Amdocal Pro  is a fixed-dose combination antihypertensive indicated for the treatment of hypertension in adult patients who require combination therapy to achieve adequate blood pressure control.

Evidence-based classification of use

• Established/guideline-supported use: Management of essential hypertension in patients not adequately controlled on a single antihypertensive agent, or as initial therapy in patients whose blood pressure is significantly above goal, where combination therapy with a beta-blocker and a calcium channel blocker is judged appropriate by the treating physician.
• Combination-dependent use: Amdocal Pro  is intended for patients already established on, or determined to need, both a beta-1 selective blocker and a dihydropyridine calcium channel blocker; it is not intended as first-line monotherapy substitution without individualized assessment.
• Adjunct benefit: In patients with hypertension and concomitant stable angina or certain arrhythmias requiring rate control, the beta-blocker component of Amdocal Pro  may provide additional symptomatic benefit, though this is not a primary approved indication for the fixed-dose product itself.

Amdocal Pro  is not indicated for hypertensive emergencies, initial therapy in treatment-naive patients without prior assessment of individual component response, or as a substitute for lifestyle modification.

Bisoprolol Fumarate + Amlodipine Besilate tablets combine two active pharmaceutical ingredients in a single fixed-dose formulation:

• Bisoprolol Fumarate - a cardioselective beta-1 adrenergic receptor blocker.
• Amlodipine Besilate - a long-acting dihydropyridine calcium channel blocker.

Locally marketed strengths of Bisoprolol Fumarate + Amlodipine Besilate typically combine bisoprolol 2.5 mg or 5 mg with amlodipine 5 mg or 10 mg per tablet; exact strengths vary by manufacturer and market authorization, and the prescribed strength should always be confirmed against the dispensed product label.

Amdocal Pro  is an oral fixed-dose combination product developed to simplify antihypertensive therapy for patients who need both a beta-blocker and a calcium channel blocker to control blood pressure. By combining bisoprolol fumarate and amlodipine besilate in a single tablet, Amdocal Pro  reduces pill burden and may improve adherence compared with taking the two components separately.

Bisoprolol fumarate works primarily by reducing heart rate and cardiac output through selective blockade of beta-1 adrenergic receptors in the heart, while amlodipine besilate works by relaxing vascular smooth muscle through inhibition of calcium influx, producing peripheral vasodilation. The complementary mechanisms allow effective blood pressure lowering with a lower dose of each component than might be required with either drug alone.

Amdocal Pro  belongs to the therapeutic class of fixed-dose antihypertensive combinations, pairing a cardioselective beta-1 adrenergic blocker (bisoprolol fumarate) with a dihydropyridine calcium channel blocker (amlodipine besilate).

Bisoprolol Fumarate + Amlodipine Besilate combines two antihypertensive agents with complementary and synergistic mechanisms of action.

Bisoprolol fumarate

Bisoprolol is a highly selective beta-1 adrenergic receptor antagonist. At therapeutic doses it competitively blocks catecholamine stimulation of beta-1 receptors predominantly located in cardiac tissue, reducing heart rate, myocardial contractility, and cardiac output, and suppressing renin release from the kidney, which together lower blood pressure.

Amlodipine besilate

Amlodipine is a long-acting dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Its predominant effect is relaxation of vascular smooth muscle, resulting in a decrease in peripheral vascular resistance and blood pressure, with a gradual onset of action and a long duration allowing once-daily dosing.

Used together in Bisoprolol Fumarate + Amlodipine Besilate, the beta-blocker component helps counteract the reflex sympathetic activation and mild reflex tachycardia that can occasionally accompany dihydropyridine calcium channel blocker use, while the calcium channel blocker component provides additional vasodilatory blood pressure lowering beyond what beta-blockade alone achieves.

Amdocal Pro  tablets should be taken orally, once daily, at approximately the same time each day, with or without food. Tablets should be swallowed whole with a glass of water and should not be crushed or chewed unless the product labeling specifically permits this. If a dose is missed, it should be taken as soon as remembered unless it is close to the time of the next dose, in which case the missed dose should be skipped; doses should never be doubled.

Amdocal Pro  carries the interaction profiles of both bisoprolol fumarate and amlodipine besilate. Only well-established, clinically significant interactions are listed below.

• Rate-limiting calcium channel blockers (verapamil, diltiazem): Concomitant use with the beta-blocker component of Amdocal Pro  can cause additive negative effects on heart rate, AV conduction, and myocardial contractility, risking severe bradycardia, AV block, or heart failure; concurrent use generally requires close monitoring or avoidance.
• Digoxin: Additive slowing of AV conduction with the beta-blocker component of Amdocal Pro  can increase the risk of bradycardia; heart rate should be monitored.
• Clonidine: If clonidine is being withdrawn in a patient on Amdocal Pro , the beta-blocker component should be discontinued several days before clonidine to avoid a risk of rebound hypertension.
• Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir, clarithromycin): Can increase plasma concentrations of the amlodipine component of Amdocal Pro , increasing the risk of hypotension and edema; dose reduction or closer monitoring may be needed.
• Strong CYP3A4 inducers (e.g. rifampin): Can reduce plasma concentrations of the amlodipine component of Amdocal Pro , reducing antihypertensive effect.
• Simvastatin: The amlodipine component of Amdocal Pro  increases simvastatin exposure; simvastatin dose should generally be limited to 20 mg daily in patients taking Amdocal Pro .
• NSAIDs: May reduce the antihypertensive effect of Amdocal Pro  and increase the risk of renal impairment, particularly in volume-depleted or elderly patients.
• Insulin and oral antidiabetic agents: The beta-blocker component of Amdocal Pro  can mask the adrenergic warning signs of hypoglycemia (see Precautions and Warnings); blood glucose should be monitored more closely.
• Other antihypertensives, alpha-blockers, and general anesthetics: Additive blood-pressure-lowering and hypotensive effects are possible with Amdocal Pro ; dose adjustment and monitoring may be required.

Side effects of Amdocal Pro  reflect the combined profiles of bisoprolol fumarate and amlodipine besilate.

• Common: Peripheral (ankle) edema, fatigue, dizziness, headache, bradycardia, flushing, palpitations.
• Less common: Cold extremities, gastrointestinal disturbance (nausea, abdominal discomfort), sleep disturbance, mood changes, hypotension, gingival hyperplasia.
• Rare but important: Bronchospasm (particularly in patients with reactive airway disease), significant AV conduction disturbances, worsening heart failure, erectile dysfunction.

Peripheral edema from the amlodipine component is dose-related and a common reason patients discontinue Amdocal Pro ; fatigue, dizziness, and bradycardia relate mainly to the bisoprolol component and are most prominent at treatment initiation or after dose increases.

Pregnancy: Amdocal Pro  should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus. Beta-blockers, including bisoprolol, can reduce placental perfusion and have been associated with fetal and neonatal effects such as bradycardia, hypoglycemia, and growth restriction when used in pregnancy; data on amlodipine in human pregnancy are limited. A physician should be consulted before use in pregnancy or if pregnancy is planned or confirmed while taking Amdocal Pro .

Lactation: Both bisoprolol and amlodipine pass into breast milk in small amounts. Amdocal Pro  should be used during breastfeeding only after consulting a physician, who will weigh the benefits of treatment against the potential risk to the nursing infant, with the infant monitored for signs such as bradycardia if maternal use continues.

The following precautions apply to Amdocal Pro :

• Abrupt discontinuation: The beta-blocker component of Amdocal Pro  should not be stopped abruptly, as this can precipitate rebound hypertension, angina, arrhythmia, or myocardial ischemia in susceptible patients; the dose should be tapered gradually under medical supervision when discontinuing.
• Bradycardia and AV conduction effects: Amdocal Pro  can slow heart rate and impair AV conduction; heart rate should be monitored, particularly when co-administered with other rate-limiting drugs (see Interactions).
• Peripheral edema: Dose-dependent ankle swelling from the amlodipine component is common and is a frequent reason for discontinuing Amdocal Pro ; patients should report significant or worsening swelling.
• Masking of hypoglycemia: The beta-blocker component of Amdocal Pro  can blunt the tachycardia and tremor that normally warn of hypoglycemia in patients with diabetes; blood glucose should be monitored more closely.
• Reactive airway disease: Even cardioselective beta-blockers such as the bisoprolol component of Amdocal Pro  can, at higher doses, provoke bronchospasm in patients with asthma or chronic obstructive pulmonary disease; Amdocal Pro  should be used with caution and the lowest effective dose in such patients.
• Hepatic impairment: Because amlodipine is extensively hepatically metabolized, patients with hepatic impairment should be started on the lowest strength of Amdocal Pro  with slower titration and closer monitoring.
• Severe aortic stenosis: Caution is advised, as the vasodilatory effect of the amlodipine component in Amdocal Pro  may reduce coronary perfusion pressure in patients with severe aortic stenosis; use should be individualized.
• Heart failure: Amdocal Pro  should be used cautiously and only in stable, compensated heart failure patients, with careful monitoring for clinical deterioration.
• Fatigue and dizziness: These are most common at treatment initiation or after a dose increase; patients should be cautious with driving or operating machinery until they know how Amdocal Pro  affects them.
• Surgery and anesthesia: The prescribing physician and anesthesiologist should be informed that the patient is taking Amdocal Pro , as the beta-blocker component can interact with anesthetic agents to increase the risk of hypotension and bradycardia.

Overdose of Amdocal Pro  may cause severe bradycardia, hypotension, acute heart failure, bronchospasm, hypoglycemia (from the bisoprolol component), and marked hypotension with reflex tachycardia progressing to shock and metabolic acidosis (from the amlodipine component). Any suspected overdose of Amdocal Pro  is a medical emergency.

Patients or caregivers should seek immediate medical attention or contact emergency services/poison control if an overdose of Amdocal Pro  is suspected. Management is supportive and should be carried out in a hospital setting; it may include cardiac monitoring, gastric decontamination if presenting soon after ingestion, intravenous fluids, and treatments for bradycardia (such as atropine or glucagon) or refractory hypotension/shock (such as vasopressors and calcium administration) as directed by treating physicians. Do not attempt to manage a suspected overdose of Amdocal Pro  at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: Amdocal Pro  should generally be started at the lowest available strength in elderly patients, who may be more sensitive to blood-pressure-lowering and bradycardic effects; dose titration should be gradual with close monitoring.
• Renal impairment: Individual component titration and caution are advised in significant renal impairment before switching to Amdocal Pro  (see Dosage and Administration).
• Hepatic impairment: Lower starting dose and slower titration are recommended (see Precautions and Warnings).
• Pediatric patients: Safety and efficacy of Amdocal Pro  have not been established in children; it is not recommended for pediatric use.
• Diabetic patients: Closer blood glucose monitoring is advised because the beta-blocker component can mask hypoglycemia symptoms (see Precautions and Warnings).

Amdocal Pro  is intended for long-term, chronic maintenance treatment of hypertension rather than short-term or as-needed use. Blood pressure control and tolerability should be reassessed periodically by the treating physician, who will determine whether continued therapy, dose adjustment, or a change in regimen is appropriate. Amdocal Pro  should not be stopped abruptly without medical guidance (see Precautions and Warnings).

Bisoprolol Fumarate + Amlodipine Besilate combines a cardioselective beta-1 adrenergic receptor blocker (bisoprolol fumarate) with a dihydropyridine calcium channel blocker (amlodipine besilate); together they form a fixed-dose combination antihypertensive.

Bisoprolol Fumarate + Amlodipine Besilate lowers blood pressure through two complementary mechanisms. The bisoprolol fumarate component selectively blocks beta-1 adrenergic receptors in the heart, reducing heart rate, cardiac contractility, and renin release. The amlodipine besilate component blocks L-type calcium channels in vascular smooth muscle, causing peripheral arterial vasodilation and reducing systemic vascular resistance. Together, the two mechanisms in Bisoprolol Fumarate + Amlodipine Besilate produce blood pressure lowering that is generally greater than either component alone, with the beta-blocker also helping to attenuate any reflex tachycardia associated with the vasodilatory effect of amlodipine.

Safety and efficacy of Amdocal Pro  have not been established in pediatric patients. Amdocal Pro  is not recommended for use in children or adolescents, and should be avoided in this population until further safety and efficacy data are available.